Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Novo Nordisk Says US Launch ‘Encouraging’ as Profit Drops

By Drug Discovery Trends Editor | April 29, 2016

The world’s largest maker of diabetes treatments, Novo Nordisk, said on Friday that the US launch of ultra-long acting insulin Tresiba had been “encouraging” as it reported a drop in first quarter profit.

Net profit fell four percent to 9.46 billion kroner (1.27 billion euros, $1.45 billion), reflecting one-off gains last year from the spinoff of its IT services arm NNIT, but came in ahead of a Bloomberg analyst consensus of 9.15 billion kroner.

“We are pleased with the results during the first quarter of 2016 where Victoza and Tresiba both delivered significant growth,” chief executive Lars Rebien Sorensen said in a statement.

The company said operating profit was expected to grow between one and five percent in Danish kroner this year, down from a previous forecast of four to eight percent, due to currency effects.

“In the US, where Tresiba was broadly launched in January 2016, early feedback from patients and prescribers is encouraging and the product has achieved wide formulary coverage,” the group said.

While all regions had contributed to sales growth, the US market had been “the main contributor”, accounting for 64 percent of growth measured in local currencies, it said.

“Tresiba has had a nice start in the US market,” Sydbank analyst Soren Lontoft Hansen told Danish news agency Ritzau.

“Not least since it has been priced slightly above the world’s best-selling diabetes drug (Sanofi’s) Lantus, and Novo Nordisk is not willing to give big rebates,” he added.

Novo Nordisk holds a 46 percent share of the international insulin market, which has swelled on the back of a global diabetes epidemic.

The number of adults estimated to be living with the disease nearly quadrupled between 1980 and 2014 to 422 million, the World Health Organization (WHO) said earlier this month.

The explosion in prevalence was because of worldwide changes “in the way people eat, move and live,” the UN health agency said in its first-ever global report on the disease.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE